Treatment of Systemic Mastocytosis

Disease Classification and Initial Management

• The National Comprehensive Cancer Network recommends that systemic mastocytosis be classified into indolent SM, smoldering SM, and advanced forms, including aggressive SM, SM with associated hematologic neoplasm, and mast cell leukemia 1
• Referral to specialized centers with expertise in mastocytosis management is strongly recommended for all patients, as stated by the National Comprehensive Cancer Network 2, 3
• All patients should carry two epinephrine auto-injectors and be counseled about avoiding triggers of mast cell activation, according to the National Comprehensive Cancer Network 4, 5
• Multidisciplinary collaboration with subspecialists is essential for optimal patient care, as recommended by the National Comprehensive Cancer Network 3

Treatment for Indolent and Smoldering Systemic Mastocytosis

• First-line treatment for indolent and smoldering systemic mastocytosis focuses on controlling mast cell activation symptoms with anti-mediator drugs, such as H1 antihistamines, H2 antihistamines, oral cromolyn sodium, leukotriene receptor antagonists, aspirin, and omalizumab, as recommended by the National Comprehensive Cancer Network 6, 7, 4, 2
• Regular follow-up with history, physical exam, and labs every 6-12 months is recommended for patients with indolent and smoldering systemic mastocytosis, according to the National Comprehensive Cancer Network 6, 1
• DEXA scan every 1-3 years is recommended for patients with osteopenia or osteoporosis, as stated by the National Comprehensive Cancer Network 6
• Assessment of symptom burden using validated tools, such as MSAF and MQLQ, is essential for optimal patient care, as recommended by the National Comprehensive Cancer Network 6

Treatment for Advanced Systemic Mastocytosis

• Midostaurin is FDA and EMA approved for advanced systemic mastocytosis, as stated by the National Comprehensive Cancer Network 5
• Cladribine is particularly useful when rapid debulking of disease is required, according to the National Comprehensive Cancer Network 5
• Imatinib is only recommended if KIT D816V mutation is negative or unknown, or if eosinophilia is present with FIP1L1-PDGFRA fusion gene, as stated by the National Comprehensive Cancer Network 5
• Interferons, such as interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b, with or without prednisone, are more suitable for slowly progressive disease, according to the National Comprehensive Cancer Network 5

Common Pitfalls and Caveats

• Avoiding triggering factors for mast cell activation, such as temperature extremes, anxiety, and stress, is essential for optimal patient care, as recommended by the American Journal of Clinical Dermatology 7
• Premedications are essential before procedures, surgery, or imaging with contrast, as stated by the National Comprehensive Cancer Network 3
• Aspirin can help with certain symptoms but may trigger mast cell activation in some patients, according to the National Comprehensive Cancer Network 4
• Regular monitoring for disease progression is essential, with restaging if symptoms worsen, as recommended by the National Comprehensive Cancer Network 6

Treatment of Systemic Mastocytosis

Essential Initial Steps for All Patients

• All patients with systemic mastocytosis must be managed at specialized centers with multidisciplinary expertise involving hematologists, pathologists, allergists, dermatologists, and gastroenterologists, as recommended by the National Comprehensive Cancer Network 8, 9

Treatment for Indolent and Smoldering Systemic Mastocytosis

Monitoring and Follow-Up

• Patients require regular assessment of symptom burden using validated tools, such as the MSAF and MQLQ questionnaires, to objectively track disease impact on quality of life, as suggested by the National Comprehensive Cancer Network 10

When to Escalate Therapy

• If patients with indolent or smoldering SM develop severe, refractory mediator symptoms or progressive bone disease unresponsive to anti-mediator therapy or bisphosphonates, cladribine or pegylated interferon-alfa may be considered, despite these agents being primarily recommended for advanced disease, as per the National Comprehensive Cancer Network guidelines 10

Treatment for Advanced Systemic Mastocytosis

First-Line Cytoreductive Therapy

• Clinical trials should be strongly considered for all patients with advanced disease, particularly those investigating highly selective KIT D816 inhibitors, as recommended by the National Comprehensive Cancer Network 8

Alternative Cytoreductive Agents

• Imatinib achieved a 50% overall response rate with sustained complete responses in patients with wild-type KIT meeting criteria for well-differentiated SM, as reported by the National Comprehensive Cancer Network 9

Role of Allogeneic Hematopoietic Cell Transplantation

• Allogeneic HCT should be evaluated for patients with advanced SM after achieving adequate response to prior treatment, with myeloablative conditioning regimens being superior to reduced-intensity regimens, resulting in a 3-year overall survival of 57% across all advanced SM subtypes, as recommended by the National Comprehensive Cancer Network 8, 9
• Mast cell leukemia represents the strongest risk factor for poor outcomes post-transplant, with a 3-year overall survival of only 17%, as reported by the National Comprehensive Cancer Network 8, 9
• For SM-AHN specifically, allogeneic HCT should be considered as part of initial treatment when the associated hematologic neoplasm component itself requires transplantation or if the AHN component progresses, as suggested by the National Comprehensive Cancer Network 8, 9

Treatment of Systemic Mastocytosis

Essential Initial Management for All Patients

• The National Comprehensive Cancer Network recommends that every patient with systemic mastocytosis must carry two epinephrine auto-injectors at all times and receive counseling about avoiding mast cell activation triggers, such as temperature extremes, anxiety, physical trauma, certain medications, and alcohol 11, 12
• Multidisciplinary collaboration with allergists, hematologists, gastroenterologists, and dermatologists is mandatory for optimal outcomes in patients with systemic mastocytosis 11

Treatment Algorithm by Disease Subtype

Indolent and Smoldering Systemic Mastocytosis

• The National Comprehensive Cancer Network recommends first-line therapy focusing exclusively on controlling mast cell mediator symptoms with anti-mediator drugs, not cytoreduction, for patients with indolent and smoldering systemic mastocytosis 11
• Primary anti-mediator therapy includes H1 antihistamines, such as cetirizine, hydroxyzine, or diphenhydramine, as foundation therapy for patients with indolent and smoldering systemic mastocytosis 11, 12
• H2 antihistamines, such as ranitidine or famotidine, may be added for gastrointestinal symptoms or refractory pruritus in patients with indolent and smoldering systemic mastocytosis 11, 12
• Oral cromolyn sodium may be used for gastrointestinal symptoms, such as diarrhea and abdominal cramping, in patients with indolent and smoldering systemic mastocytosis 11
• Leukotriene receptor antagonists, such as montelukast, may be used for flushing and respiratory symptoms in patients with indolent and smoldering systemic mastocytosis 11
• Aspirin may be used for flushing episodes in patients with indolent and smoldering systemic mastocytosis, but only after confirming tolerance, as it can trigger mast cell activation in some patients 11, 12
• Omalizumab may be used for refractory anaphylaxis or severe mediator symptoms in patients with indolent and smoldering systemic mastocytosis 11

Advanced Systemic Mastocytosis (Aggressive SM, SM-AHN, Mast Cell Leukemia)

• The National Comprehensive Cancer Network recommends midostaurin 100 mg orally twice daily with food as the FDA-approved first-line cytoreductive therapy for all advanced SM subtypes 11
• Alternative cytoreductive agents, such as cladribine, imatinib, and interferons, may be used when midostaurin is not tolerated or available for patients with advanced systemic mastocytosis 11
• Clinical trial enrollment should be strongly prioritized for all advanced SM patients, particularly trials investigating highly selective KIT D816 inhibitors 11

Perioperative Management

• The National Comprehensive Cancer Network recommends multidisciplinary management with surgical, anesthesia, and perioperative medical teams for patients with systemic mastocytosis undergoing surgery 12
• Preoperative preparation should include careful review of prior anesthetic records to identify known triggers, premedication with anxiolytics, H1 and H2 antihistamines, and possibly corticosteroids for patients with systemic mastocytosis 12
• Safer perioperative agents, such as propofol, sevoflurane, and fentanyl, should be used for patients with systemic mastocytosis 12

Common Pitfalls and Caveats

• The National Comprehensive Cancer Network recommends avoiding critical errors, such as using antibody titers or serum tryptase levels alone to guide treatment decisions, and not initiating cytoreductive therapy for indolent SM based solely on elevated tryptase or bone marrow mast cell burden without documented organ damage or refractory symptoms 11
• Aspirin can paradoxically trigger mast cell activation in some patients despite being therapeutic in others, and tolerance should always be tested before regular use 11, 12